AbbVie 3D regimen cures recurrent HCV in most liver transplant recipients without cirrhosis
NHS urgently needs to make PrEP available, say HIV prevention organisations
Tenofovir continues to suppress hepatitis B virus for eight years
Daclatasvir + sofosbuvir demonstrates good cure rate for genotype 3 hepatitis C
Positive response to 'gift tokens for undetectable viral load' trial
AbbVie 3D regimen and sofosbuvir/ribavirin show high cure rates for HCV in people with HIV co-infection
Sofosbuvir + GS-5816 for 12 weeks shows high HCV cure rates, but 8 weeks is less effective for some patients
HIV in the UK: 76% diagnosed, 90% on treatment, 90% undetectable
Adding pegylated interferon to tenofovir improves odds of HBsAg loss in hepatitis B patients
